Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2025)
Historic Receivables - Other for Allogene Therapeutics (ALLO) over the last 6 years, with Q3 2025 value amounting to $23.5 million.
- Allogene Therapeutics' Receivables - Other rose 516.13% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 516.13%. This contributed to the annual value of $20.8 million for FY2024, which is N/A changed from last year.
- As of Q3 2025, Allogene Therapeutics' Receivables - Other stood at $23.5 million, which was up 516.13% from $23.5 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Receivables - Other ranged from a high of $23.5 million in Q2 2025 and a low of $1.2 million during Q1 2023
- Moreover, its 5-year median value for Receivables - Other was $9.4 million (2022), whereas its average is $12.1 million.
- Per our database at Business Quant, Allogene Therapeutics' Receivables - Other soared by 14285.71% in 2022 and then crashed by 8723.4% in 2023.
- Over the past 5 years, Allogene Therapeutics' Receivables - Other (Quarter) stood at $4.1 million in 2021, then tumbled by 63.41% to $1.5 million in 2022, then decreased by 20.0% to $1.2 million in 2023, then skyrocketed by 1631.08% to $20.8 million in 2024, then rose by 12.99% to $23.5 million in 2025.
- Its last three reported values are $23.5 million in Q3 2025, $23.5 million for Q2 2025, and $21.6 million during Q1 2025.